title: Dexmedetomidine for the prevention of shivering during spinal anesthesia.
abstract: OBJECTIVE
  The aim of this study was to evaluate the effect of dexmedetomidine on shivering during spinal anesthesia.
  
  
  METHODS
  Sixty patients (American Society of Anesthesiologists physical status I or II, aged 18-50 years), scheduled for elective minor surgical operations under spinal anesthesia with hyperbaric bupivacaine, were enrolled. They were administered saline (group C, n = 30) or dexmedetomidine (group D, n = 30). Motor block was assessed using a Modified Bromage Scale. The presence of shivering was assessed by a blinded observer after the completion of subarachnoid drug injection.
  
  
  RESULTS
  Hypothermia was observed in 21 patients (70%) in group D and in 20 patients (66.7%) in group C (p = 0.781). Three patients (10%) in group D and 17 patients (56.7%) in group C experienced shivering (p = 0.001). The intensity of shivering was lower in group D than in group C (p = 0.001). Time from baseline to onset of shivering was 10 (5-15) min in group D and 15 (5-45) min in group C (p = 0.207).
  
  
  CONCLUSIONS
  Dexmedetomidine infusion in the perioperative period significantly reduced shivering associated with spinal anesthesia during minor surgical procedures without any major adverse effect during the perioperative period. Therefore, we conclude that dexmedetomidine infusion is an effective drug for preventing shivering and providing sedation in patients during spinal anesthesia.
authors.affiliation: Department of Anesthesiology, School of Medicine, Fatih University, Ankara, Turkey.
authors.forename: Burhanettin
authors.initials: B
authors.lastname: Usta
authors.forename: Muhammet
authors.initials: M
authors.lastname: Gozdemir
authors.forename: Ruveyda Irem
authors.initials: RI
authors.lastname: Demircioglu
authors.forename: Bunyamin
authors.initials: B
authors.lastname: Muslu
authors.forename: Huseyin
authors.initials: H
authors.lastname: Sert
authors.forename: Adnan
authors.initials: A
authors.lastname: Yaldiz
mesh_terms: D000293:Adolescent; D058647:Adrenergic alpha-2 Receptor Agonists / Q000627:therapeutic use*; D000328:Adult; D000775:Anesthesia, Spinal / Q000009:adverse effects*; D000779:Anesthetics, Local / Q000009:adverse effects; D001831:Body Temperature / Q000187:drug effects; D001833:Body Temperature Regulation / Q000187:drug effects / Q000502:physiology; D002045:Bupivacaine / Q000009:adverse effects; D016022:Case-Control Studies; D016009:Chi-Square Distribution; D020927:Dexmedetomidine / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D011184:Postoperative Period; D012768:Shivering / Q000187:drug effects*; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D058647:Adrenergic alpha-2 Receptor Agonists; D000779:Anesthetics, Local; D020927:Dexmedetomidine; D002045:Bupivacaine